Ecotoxicity and Mutagenicity Assessment of Novel Antifungal Agents VT-1161 and T-2307 DOI Creative Commons
Edith Guadalupe Padilla Suarez, Antonietta Siciliano,

Marisa Spampinato

и другие.

Molecules, Год журнала: 2024, Номер 29(19), С. 4739 - 4739

Опубликована: Окт. 7, 2024

Antifungal substances are essential for managing fungal infections in humans, animals, and plants, their usage has significantly increased due to the global rise infections. However, extensive application of antifungal agents pharmaceuticals, personal care products, agriculture led widespread environmental dissemination through various pathways, such as excretion, improper disposal, agricultural runoff. Despite advances wastewater treatment, many compounds persist environment, affecting non-target organisms contributing resistance development. This study investigates impact two novel agents, VT-1161 T-2307, recently introduced alternatives treating resistant

Язык: Английский

New treatment options for critically important WHO fungal priority pathogens DOI Creative Commons
Lisa Kriegl, Matthias Egger, Johannes Boyer

и другие.

Clinical Microbiology and Infection, Год журнала: 2024, Номер unknown

Опубликована: Март 1, 2024

BackgroundYet often overlooked in public health discourse, fungal infections pose a crucialglobal disease burden associated with annual mortality rates approximately equal to tuberculosis and HIV. In response, the World Health Organization (WHO) published its first global priority list of pathogens 2022 assigning Aspergillus fumigatus, Candida albicans, auris, Cryptococcus neoformans critical group.ObjectivesThis review provides succinct insights on novel antifungals development, aiming contribute valuable information perspectives focus recent clinical findings new treatment approaches for members WHO pathogen list.SourcesPubMed literature search using "Aspergillus fumigatus," "Cryptococcus neoformans," "Candida auris," albicans," along names antifungal substances, including "fosmanogepix", "ibrexafungerp", "opelconazole", "oteseconazole", "MAT2203", "olorofim", "rezafungin" was conducted.ContentForeach pathogen, current issues data from trials are covered. The remarkable development three therapeutics recently receiving Food Drug Administration (FDA) approval (ibrexafungerp -June 2021, oteseconazole -April 2022, rezafungin -March 2023) is outlined, two more exciting namely olorofim fosmanogepix expecting within next years. Ibrexafungerp, have additionally been granted orphan drug status by European Medicines Agency (EMA) Europe -November -July -January 2024).ImplicationsWhile limited number targets emergence resistance posed challenges treatment, drugs such as ibrexafungerp, rezafungin, fosmanogepix, or shown promising efficacy. These not only provide alternative options invasive but also alleviate outpatient settings. More data, implementation stewardship programs, surveillance, utilization agriculture necessary prevent ensure safety efficacy these agents.

Язык: Английский

Процитировано

21
Candida albicans skin infection in diabetic patients: An updated review of pathogenesis and management DOI
Sakina Shahabudin, Nina Suhaity Azmi, Mohd Nizam Lani

и другие.

Mycoses, Год журнала: 2024, Номер 67(6)

Опубликована: Июнь 1, 2024

Candida species, commensal residents of human skin, are recognized as the cause cutaneous candidiasis across various body surfaces. Individuals with weakened immune systems, particularly those immunosuppressive conditions, significantly more susceptible to this infection. Diabetes mellitus, a major metabolic disorder, has emerged critical factor inducing immunosuppression, thereby facilitating colonization and subsequent skin infections. This comprehensive review examines prevalence different types albicans-induced in diabetic patients. It explores underlying mechanisms pathogenicity offers insights into recommended preventive measures treatment strategies. notably increases vulnerability oral oesophageal candidiasis. Additionally, it can precipitate vulvovaginal females, balanitis males, diaper young children diabetes. Diabetic individuals may also experience candidal infections on their nails, hands feet. Notably, diabetes appears be risk for intertrigo syndrome obese periodontal disorders denture wearers. In conclusion, intricate relationship between necessitates understanding strategize effective management planning. Further investigation interdisciplinary collaborative efforts crucial address multifaceted challenge uncover novel approaches treatment, prevention both health including development safer antifungal agents.

Язык: Английский

Процитировано

7
Vulvovaginal Candidiasis-An Overview of Current Trends and the Latest Treatment Strategies DOI

Vasundhara B Bhosale,

Akshada Amit Koparde, Vandana M Thorat

и другие.

Microbial Pathogenesis, Год журнала: 2025, Номер unknown, С. 107359 - 107359

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

1
The Efficacy of Hybrid Vaginal Ovules for Co-Delivery of Curcumin and Miconazole against Candida albicans DOI Creative Commons
Brenda Maria Silva Bezerra, Sara Efigênia Dantas de Mendonça y Araújo, José de Oliveira Alves-Júnior

и другие.

Pharmaceutics, Год журнала: 2024, Номер 16(3), С. 312 - 312

Опубликована: Фев. 23, 2024

Curcumin (CUR) is a natural compound that can be combined with miconazole (MCZ) to improve vulvovaginal candidiasis (VVC) caused by Candida albicans treatment’s efficacy. This study aimed develop ureasil–polyether (U-PEO) vaginal ovules loaded CUR and MCZ for the treatment of VVC. Physicochemical characterization was performed thermogravimetry (TGA), differential thermal analysis (DTA), Fourier transform infrared spectroscopy (FTIR), in vitro release. Antifungal assays were used determine minimum inhibitory concentrations (MICs) synergism between MCZ, activity U-PEO microdilution agar diffusion. TGA results showed high stability hybrid ovules. In DTA, amorphous character possible interaction observed. FTIR no chemical incompatibility drugs. release resulted 80% 95% released within 144 h. The MICs 256 2.5 µg/mL, respectively. After combining drugs, MIC decreased four-fold 0.625 while eight-fold 32 µg/mL. Synergism confirmed fractional concentration index (FICI) equal 0.375. alone antifungal activity. U-PEO/MCZ U-PEO/CUR/MCZ greatest zones inhibition (≥18 mm). highlight potential administered at lower frequency reduced doses compared available formulations.

Язык: Английский

Процитировано

6
An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis DOI
Divisha Sharma, José A. Vázquez

Expert Opinion on Pharmacotherapy, Год журнала: 2024, Номер 25(4), С. 339 - 347

Опубликована: Март 3, 2024

Introduction Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity mortality. In addition, the emergence of drug-resistant Candida species, notably C. glabrata auris, along with limitations in available treatments, highlights urgent need for novel, effective antifungal agents.

Язык: Английский

Процитировано

5
Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy) DOI
Giacomo Ponta,

Valentina Morena,

Martina Strano

и другие.

Antimicrobial Agents and Chemotherapy, Год журнала: 2024, Номер 68(8)

Опубликована: Июль 12, 2024

Rezafungin is an echinocandin characterized by a long elimination half-life which allows for weekly administration. It has been recently approved the treatment of candidemia. Few data are available about long-term use rezafungin and its deep infections like endocarditis osteomyelitis. We describe our experience with prolonged in two azole-resistant

Язык: Английский

Процитировано

5
Comparative efficacy of antifungal drugs for the treatment of oral candidiasis in HIV-positive patients: A Bayesian network meta-analysis DOI
Jiong Lin,

Caixia Peng,

Wei-man Huang

и другие.

Medicina Clínica (English Edition), Год журнала: 2025, Номер 164(2), С. 76 - 83

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Preventing Oral Dual Biofilm Development with Innovative Bioactive Varnishes DOI Creative Commons

Tainá de Lima Costa,

Regina Maria Puppin‐Rontani, Aline Rogéria Freire de Castilho

и другие.

Journal of Functional Biomaterials, Год журнала: 2025, Номер 16(2), С. 70 - 70

Опубликована: Фев. 18, 2025

This study introduces innovative varnishes incorporating natural bioactive compounds to inhibit the formation of oral dual biofilms, a critical contributor dental caries and other diseases. The purpose this was evaluate effectiveness containing tt-farnesol, quercetin, theobromine in inhibiting mixed Streptococcus mutans Candida albicans biofilms. Mixed biofilms UA159 SC5314 were grown 96-well plates specialized culture medium. Approximately 0.2 mL experimental with A-1.5% or B-4.5% concentrations separately added wells using disposable applicator, vehicle varnish (lacking bioactives) serving as control. Biofilms incubated at 37 °C 5% CO2 for 24 h. Microbial viability determined terms colony-forming units per milliliter (CFU/mL), biofilm morphology evaluated qualitatively via scanning electron microscopy (SEM). Statistical analyses performed ANOVA/Tukey tests significance level. Varnishes A B achieved significant reductions microbial populations within (p < 0.05) compared control (C). SEM imaging revealed marked structural disruptions validating quantitative results. Higher demonstrated enhanced inhibitory effects. Bioactive enriched theobromine, tt-farnesol represent novel effective strategy development, offering promising advancement preventive dentistry.

Язык: Английский

Процитировано

0
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies DOI
Virginia Fuochi, Salvatore Furnari, Laura Trovato

и другие.

Expert Opinion on Investigational Drugs, Год журнала: 2024, Номер 33(7), С. 677 - 698

Опубликована: Май 3, 2024

Urinary tract infections (UTIs) are a prevalent health challenge characterized by the invasion and multiplication of microorganisms in urinary system. The continuous exploration novel therapeutic interventions is imperative. Advances research offer hope for revolutionizing management UTIs improving overall outcomes individuals affected these infections.

Язык: Английский

Процитировано

2
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix DOI
Benjamin August, Pramodini Kale-Pradhan

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, Год журнала: 2024, Номер 44(6), С. 467 - 479

Опубликована: Май 9, 2024

Abstract Management of invasive fungal infections is challenging with growing antifungal resistance. Broad use has resulted in greater intrinsic and acquired resistance among Candida spp. It important for clinicians to recognize the relationship between host susceptibility, site infection, profiles, specific drug pharmacokinetics pharmacodynamics, role novel agents. This narrative review covers rezafungin, ibrexafungerp, fosmanogepix management candidiasis (IC). The PubMed Database, Embase, ClinicalTrials.gov were searched January 2006 2024 using following terms: CD101, SCY‐078, fosmanogepix, APX001, candidemia, candidiasis. Review articles, prospective clinical trials, observational studies published English language reviewed. Studies evaluating pharmacology, pharmacokinetics, efficacy, safety animals humans also Promising data continues emerge support therapies IC candidemia. Rezafungin possesses a unique pharmacodynamic profile that might be advantageous compared other echinocandins, practical, once‐weekly dosing interval. Ibrexafungerp, currently approved vulvovaginal candidiasis, been studied off‐label initial encouraging. Lastly, mechanistically novel, investigational agent, may potential future option Future research needed evaluate these agents diverse patient populations.

Язык: Английский

Процитировано

2